ArticleProceedings (Baylor University. Medical Center)2026
State-level burden of early onset colorectal cancer in the US: a Global Burden of Disease study, 1980 to 2021.
Article in Proceedings (Baylor University. Medical Center), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEarly-onset colorectal cancer (EOCC) is an escalating clinical challenge. While national incidence is rising, aggregated data may obscure critical differences in mortality trends and geographic burden that are essential for clinical risk assessment.
methodsWe utilized the Global Burden of Disease (GBD) 2021 study to analyze incidence, mortality, and disability-adjusted life years (DALYs) for colorectal cancer in US adults aged <50 years. Data were stratified by fine 5-year age groups and US state from 1990 to 2021.
resultsNationally, incidence rates increased consistently across all cohorts aged 25 to 49 years from 1990 through 2021. In contrast, mortality and DALY rates exhibited a U-shaped trajectory for the 30 to 49 age strata: declining until the mid-2000s, followed by a persistent resurgence through 2021. This mortality reversal was most pronounced in the Southern Census regions. In 2021, the burden was disproportionately concentrated in East South Central and West South Central states, with Mississippi, Kentucky, and West Virginia exhibiting mortality rates up to twofold higher than states in New England or the Pacific West.
conclusionThe decoupling of incidence and mortality trends suggests that therapeutic advances are no longer sufficient to offset the accelerating incidence of EOCC in the 30 to 49 age demographic. The distinct geographic clustering of advanced disease burden warrants heightened diagnostic vigilance for symptomatic young adults, particularly in high-prevalence Southern and Appalachian regions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.